| 1 |
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al. · New England Journal of Medicine
Open access |
28 Aug 2020 |
5,214 |
| 2 |
Autoantibodies against type I IFNs in patients with life-threatening COVID-19
Paul Bastard et al. · Science
Open access752 authors |
24 Sep 2020 |
2,885 |
| 3 |
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
Faiez M. Zannad, João Pedro Ferreira, Stuart Pocock et al. · The Lancet
ReviewOpen access |
30 Aug 2020 |
1,418 |
| 4 |
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation
Christopher Paul Cannon, Deepak L. Bhatt, Jonas Oldgren et al. · New England Journal of Medicine
Open access |
27 Aug 2017 |
1,386 |
| 5 |
The State of Vaccine Confidence 2016: Global Insights Through a 67-Country Survey
Heidi Jane Larson, Alexandre de Figueiredo, Xiahong Zhao et al. · EBioMedicine
Open access |
14 Sep 2016 |
1,307 |
| 6 |
The Use of Diuretics in Heart Failure with Congestion — A Position Statement from the Heart Failure Association of the European Society of Cardiology
Wilfried Müllens, Kevin Damman, Veli‐Pekka Harjola et al. · European Journal of Heart Failure
Open access |
2019 |
1,116 |
| 7 |
Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure
Sonia H Shah et al. · Nature Communications
Open access203 authors |
9 Jan 2020 |
944 |
| 8 |
Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials
Muthiah Vaduganathan, Brian Lee Claggett, Pardeep S. Jhund et al. · The Lancet
Open access |
21 May 2020 |
671 |
| 9 |
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
Rajiv Agarwal, Peter Kolkhof, George L. Bakris et al. · European Heart Journal
Open access |
Sep 2020 |
627 |
| 10 |
Pathophysiology of COVID-19-associated acute kidney injury
Matthieu M. Legrand, Samira Bell, Lui G. Forni et al. · Nature Reviews Nephrology
ReviewOpen access |
5 Jul 2021 |
519 |
| 11 |
Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study
Emmanuelle Vidal‐Petiot, Ian Ford, Nicola Greenlaw et al. · The Lancet
Open access |
6 Sep 2016 |
488 |
| 12 |
LRRK2 in Parkinson disease: challenges of clinical trials
EDUARDO S. TOLOSA, Miquel Vila, Christine Klein et al. · Nature Reviews Neurology
Review |
24 Jan 2020 |
465 |
| 13 |
The systemic nature of CKD
Carmine Zoccali, Raymond C. Vanholder, Ziad A. Massy et al. · Nature Reviews Nephrology
Review |
23 Apr 2017 |
450 |
| 14 |
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction
Milton Packer, Stefan D. Anker, Javed Butler et al. · Circulation
Open access |
21 Oct 2020 |
442 |
| 15 |
Organ Dysfunction, Injury and Failure in Acute Heart Failure: From Pathophysiology to Diagnosis and Management. A Review on Behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
Veli‐Pekka Harjola et al. · European Journal of Heart Failure
Open access |
30 May 2017 |
431 |
| 16 |
Evaluation of Kidney Function Throughout the Heart Failure Trajectory – A Position Statement from the Heart Failure Association of the European Society of Cardiology
Wilfried Müllens, Kevin Damman, Jeffrey Moore Testani et al. · European Journal of Heart Failure
Open access |
7 Jan 2020 |
409 |
| 17 |
Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial
Stephan Ehrmann et al. · The Lancet Respiratory Medicine
Open access184 authors |
20 Aug 2021 |
405 |
| 18 |
Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants
Simon B. Drysdale, Katrina Cathie, Florence Flamein et al. · New England Journal of Medicine
Open access |
27 Dec 2023 |
386 |
| 19 |
Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial
Rajiv Agarwal, Patrick Rossignol, Alain Romero et al. · The Lancet
Open access |
15 Sep 2019 |
375 |
| 20 |
Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment
Eva M. Boorsma, Jozine M. ter Maaten, Kevin Damman et al. · Nature Reviews Cardiology
ReviewOpen access |
15 May 2020 |
369 |
| 21 |
Vitamin D in Chronic Kidney Disease and Dialysis Patients
Guillaume Jean, Jean Souberbielle, Charles Chazot · Nutrients
Open access |
25 Mar 2017 |
363 |
| 22 |
Trial of Cinpanemab in Early Parkinson’s Disease
Anthony E. Lang et al. · New England Journal of Medicine
Open access |
3 Aug 2022 |
360 |
| 23 |
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status
Stefan D. Anker, Javed Butler, Gerasimos S Filippatos et al. · Circulation
Open access |
11 Nov 2020 |
359 |
| 24 |
Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial
Milton Packer, Javed Butler, Faiez M. Zannad et al. · Circulation
Open access |
29 Aug 2021 |
355 |
| 25 |
Heart failure drug treatment
Patrick Rossignol, Adrian F. Hernandez, SCOTT D. SOLOMON et al. · The Lancet
Open access |
Mar 2019 |
351 |
| 26 |
Trial of Lixisenatide in Early Parkinson’s Disease
Wassilios G. Meissner et al. · New England Journal of Medicine
|
3 Apr 2024 |
347 |
| 27 |
Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease
Faiez M. Zannad, Stefan D. Anker, William M. Byra et al. · New England Journal of Medicine
Open access |
27 Aug 2018 |
347 |
| 28 |
Vaccine Hesitancy Among General Practitioners and Its Determinants During Controversies: A National Cross-sectional Survey in France
Pierre Verger, Lisa Fressard, Fanny Collange et al. · EBioMedicine
Open access |
23 Jun 2015 |
346 |
| 29 |
Prevalence of obesity among adult inpatients with COVID-19 in France
Cyrielle Caussy, François N. Pattou, Florent Wallet et al. · The Lancet Diabetes & Endocrinology
Open access |
18 May 2020 |
342 |
| 30 |
Cardiorenal Syndrome Revisited
Faiez M. Zannad, Patrick Rossignol · Circulation
Open access |
28 Aug 2018 |
338 |
| 31 |
Artificial sweeteners and cancer risk: Results from the NutriNet-Santé population-based cohort study
Charlotte Debras, Eloi Chazelas, Bernard Srour et al. · PLoS Medicine
Open access |
24 Mar 2022 |
335 |
| 32 |
Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial
Regina Katzenschlager, Werner H Poewe, Olivier Rascol et al. · The Lancet Neurology
Open access |
25 Jul 2018 |
334 |
| 33 |
HPV vaccination in a context of public mistrust and uncertainty: a systematic literature review of determinants of HPV vaccine hesitancy in Europe
Emilie Karafillakis, Clarissa Simas, Caitlin Jarrett et al. · Human Vaccines & Immunotherapeutics
ReviewOpen access |
11 Jan 2019 |
326 |
| 34 |
Respiratory Syncytial Virus and Other Respiratory Viral Infections in Older Adults With Moderate to Severe Influenza-like Illness
Ann Regina Falsey et al. · The Journal of Infectious Diseases
Open access |
29 Jan 2014 |
304 |
| 35 |
Physical Activity and Mortality in Patients With Stable Coronary Heart Disease
Ralph Stewart, Claes Held, Nermin Hadziosmanovic et al. · Journal of the American College of Cardiology
Open access |
25 Sep 2017 |
303 |
| 36 |
Worsening Heart Failure: Nomenclature, Epidemiology, and Future Directions
Stephen John Greene, Johann K Bauersachs, Jasper Jan Brugts et al. · Journal of the American College of Cardiology
Open access |
2023 |
302 |
| 37 |
Towards Better Definition, Quantification and Treatment of Fibrosis in Heart Failure. A Scientific Roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology
Rudolf A. de Boer et al. · European Journal of Heart Failure
Open access |
4 Feb 2019 |
301 |
| 38 |
Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs
Delphine Charvin, Rossella Medori, Robert A. Hauser et al. · Nature Reviews Drug Discovery
Review |
28 Sep 2018 |
295 |
| 39 |
The Clinical Significance of Interleukin-6 in Heart Failure: Results from the BIOSTAT-CHF Study
George Markousis‐Mavrogenis et al. · European Journal of Heart Failure
Open access |
14 May 2019 |
293 |
| 40 |
Inflammatory Biomarkers Interleukin‐6 and C‐Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial
Claes Held, Harvey Douglas White, Ralph Stewart et al. · Journal of the American Heart Association
Open access |
11 Oct 2017 |
293 |
| 41 |
Prognostic Value of Residual Pulmonary Congestion at Discharge Assessed by Lung Ultrasound Imaging in Heart Failure
Stefano Coiro, Patrick Rossignol, Giuseppe Ambrosio et al. · European Journal of Heart Failure
|
29 Sep 2015 |
292 |
| 42 |
Tranexamic Acid for the Prevention of Blood Loss after Cesarean Delivery
Loı̈c Sentilhes et al. · New England Journal of Medicine
Open access |
28 Apr 2021 |
285 |
| 43 |
Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, open-label, randomised, controlled trial
Stèphane Gaudry et al. · The Lancet
Open access |
Apr 2021 |
285 |
| 44 |
Integrative Assessment of Congestion in Heart Failure Throughout the Patient Journey
Nicolas Girerd, Marie‐France Seronde, Stefano Coiro et al. · JACC Heart Failure
Open access |
7 Dec 2017 |
281 |
| 45 |
Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Jennifer E. Flythe et al. · Kidney International
Open access |
8 Mar 2020 |
275 |
| 46 |
Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis
Jonatan Barrera‐Chimal, Sophie Girerd, Frédéric Jaisser · Kidney International
Open access |
12 Mar 2019 |
267 |
| 47 |
Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction
Javed Butler, Milton Packer, Gerasimos S Filippatos et al. · European Heart Journal
Open access |
23 Nov 2021 |
263 |
| 48 |
Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research
Mahesh V. Madhavan et al. · Thrombosis and Haemostasis
Open access |
30 May 2020 |
261 |
| 49 |
Effects of Icosapent Ethyl on Total Ischemic Events
Deepak L. Bhatt, Philippe Gabríel Steg, Michael J. Miller et al. · Journal of the American College of Cardiology
Open access |
18 Mar 2019 |
258 |
| 50 |
Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort
Nadège Néant et al. · Proceedings of the National Academy of Sciences
Open access |
3 Feb 2021 |
257 |